Skip to content

Psychedelic-assisted therapy: all studies

Page 215 of 294: studies 2,141 to 2,150 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Module 5: Mindfulness

Coping After COVID-19: Cognitive Behavioral Skills for Anxiety, Depression, and Adjusting to Chronic Illness November 1, 2023 Abhishek Jaywant, Lauren E. Oberlin, Stephanie Cherestal et al.

Abstract This chapter introduces mindfulness as a technique for assisting clients with persistent COVID-19 symptoms to manage their emotional distress, anxiety, and depression. Mindfulness is defined as paying attention in a particular way: on purpose, in the present moment, and non-judgmentally. It is not necessarily about relaxation or clearing the mind but rather a process of bringing...

Psychedelic Crystals in Cinema: Opening Virtual Dimensions and Potential Healing

Deleuze and Guattari Studies November 1, 2023 Erica Biolchini

This article proposes a different aesthetic state of Gilles Deleuze’s crystal-image defined as ‘psychedelic crystal’, a formation of the crystalline regime in light of the contemporary revival of scientific research exploring the healing potentialities of hallucinogenic drugs. The proposition of the psychedelic crystal occurs between Deleuze’s crystals of time, the therapeutic dimension of...

From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder

October 30, 2023 Jeremy Weleff, Julio C Nunes, Gabriel P. A. Costa et al.

The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated with countercultural movements and recreational use, recent research has shed light on the potential benefits of psychedelics in various mental health conditions. In this review, we explore the emerging role of psychedelics in the management of...

Psychedelics action and schizophrenia.

Pharmacological Reports October 30, 2023 Marzena Maćkowiak 20 citations

Abstract Psychedelics are compounds acting by serotonin 5-hydroxytryptamine (5-HT) 2A receptor activation and induce several behavioral responses. They are of special interest because of their positive effects on neuropsychiatric disorders (depression and posttraumatic stress disorder). However, several findings revealed that some psychedelic actions are similar to symptoms observed in...

DOI: 10.1007/s43440-023-00546-5 (opens in new tab) Full text (opens in new tab) Psychedelics Schizophrenia Consciousness Mental health

Memory

Psychedelic Experience October 26, 2023 Aidan Lyon

Abstract This chapter explores the idea that some memory recollections count as psychedelic experiences and that they can occur spontaneously, during and after meditation, and as a result of consuming psychedelic substances. The chapter also introduces the concept of mindfulness and unpacks the deep and important connection between mindfulness and memory. This analysis of mindfulness is then...

Psychedelic and nutraceutical interventions as therapeutic strategies for military-related mild traumatic brain injuries

Journal of Military, Veteran and Family Health October 25, 2023 Amy C. Reichelt, Eric Vermetten, Benjamin T. Dunkley 5 citations

LAY SUMMARY Concussion is a type of acquired brain injury that is common in the military, as well as among civilians and contact sport athletes, and is defined by a transient impairment in mental function. Nevertheless, concussion presents a considerable health burden, and a small minority of people suffer from continued impairment. Repetitive sub-concussive head injury is a known risk factor...

DOI: 10.3138/jmvfh-2022-0084 (opens in new tab) Concussion Traumatic brain injury Psychological intervention Intervention counseling +8

Cardiovascular safety of psychedelic medicine: current status and future directions

Pharmacological Reports October 24, 2023 Agnieszka Wsół 56 citations

Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and...

Evidence that Moved Psychedelic Medicine from the Fringe to the Mainstream in 2022

European Psychiatry October 23, 2023 Michael P. Bogenschutz

Abstract Interest in possible clinical uses for psychedelic drugs has grown steadily over the past decade. Although impressive findings from small studies stimulated considerable speculation and provided a strong justification for further study of psychedelic treatments, until very recently there was a dearth of high-quality evidence for their efficacy, mechanisms of action, and appropriate...

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges

Frontiers in Psychiatry October 19, 2023 Brian S. Barnett, Anahita Bassir Nia, Nathan Sackett et al. 1 citation

Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.

Scientific Reports October 14, 2023 Nathalie M. Rieser, Ladina P Gubser, Flora Moujaes et al. 14 citations

Research into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain-behavior relationships linking psilocybin-induced brain changes to subjective drug-induced effects have not been established. Furthermore, it is unclear if the acute neural effects are dependent on individual heterogeneity in baseline characteristics. To address this, we...

DOI: 10.1038/s41598-023-44153-z (opens in new tab) Full text (opens in new tab) Psychedelics Personalized medicine Brain imaging Mental health